(Q113888887)

English

The Combination of Terbutaline and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

clinical trial

In more languages

edit

Statements

instance of

clinical trial

0 references

title

The Combination of Terbutaline and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia (English)

0 references

medical condition

thrombocytopenia

0 references

start time

8 July 2020

0 references

end time

31 March 2021

0 references

number of participants

40

0 references

research intervention

terbutaline

0 references

danazol

0 references

bronchodilator

0 references

peripheral nervous system agent

0 references

antiasthmatic

0 references

respiratory system agents

0 references

tocolytic uterine relaxants

0 references

reproductive control agents

0 references

beta2-adrenergic agonist

0 references

adrenergic beta-agonists

0 references

adrenergic agent

0 references

neurotransmitter agent

0 references

mechanism of action

0 references

estrogen antagonist

0 references

hormone antagonist

0 references

hormones, hormone substitutes, and hormone antagonists

0 references

clinical trial phase

phase II clinical trial

0 references

research subject recruitment status

unknown

0 references

minimum age

18 year

0 references

study type

interventional study

0 references

Identifiers

ClinicalTrials.gov ID

NCT04481282

0 references

(Q113888887)

The Combination of Terbutaline and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)